Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALLTrial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL

The New England journal of medicine Published October 15, 2026 Study authors: Chiaretti Sabina, Piciocchi Alfonso, Skert Cristina, Leoncin Matteo, Borlenghi Erika, Cattaneo Chiar… PubMed ↗ NCT04722848 ↗ DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Ponatinib plus blinatumomab improved event-free survival versus imatinib plus chemotherapy in Ph-positive ALL.

This Phase 3 randomized trial enrolled 236 adults with Philadelphia-positive acute lymphoblastic leukemia to compare a chemotherapy-free regimen of ponatinib plus blinatumomab against standard imatinib plus chemotherapy.

The primary endpoint, 24-month event-free survival, reached 86% with ponatinib plus blinatumomab compared with 67% for imatinib plus chemotherapy (P<0.001). Secondary outcomes also favored the experimental arm: survival without measurable residual disease was 68% versus 42%, complete hematologic response at end of induction was 94% versus 79%, and molecular response after blinatumomab consolidation was 71% versus 49%. Overall survival was 90% versus 85%, and the cumulative incidence of relapse was 5% versus 13%.

Median follow-up was 23.7 months. Safety data, including adverse events and discontinuations, were not reported in the abstract. A key limitation is that crossover to the intervention group was permitted for control patients with persistent or reappearing measurable residual disease; among 31 crossover patients, molecular response was 64%.

The findings support a frontline chemotherapy-free targeted and immunotherapeutic approach over imatinib plus chemotherapy in this population. Given the Phase 3 randomized design, the results suggest a causal relationship, though the median follow-up duration should be considered when interpreting long-term outcomes.

How this fits prior evidence

How this fits prior evidence: This finding extends the use of blinatumomab in ALL. While prior coverage noted that blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL, and blinatumomab significantly improves 4-year event-free survival in pediatric high-risk B-cell ALL, this study provides evidence for a different regimen in an adult Ph-positive population. It specifically addresses the utility of combining ponatinib with blinatumomab as a chemotherapy-free alternative to imatinib-based regimens.

A Phase 3 clinical trial looked at a new treatment approach for adults with Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL). Researchers compared a combination of ponatinib and blinatumomab against the standard treatment of imatinib and chemotherapy. The study included 236 patients and followed them for a median of 23.7 months.

The results showed that the ponatinib and blinatumomab group had better outcomes across several measures. Specifically, 86% of patients in the new treatment group reached 24-month event-free survival, compared to 67% in the control group. Additionally, the new treatment showed a lower rate of relapse, with only 5% compared to 13% in the group receiving imatinib and chemotherapy.

While the study shows a clear benefit for this combination, it is important to note that patients in the control group who did not respond well were allowed to switch to the new treatment. Because this was a controlled trial, the results are promising, but patients should talk to their doctors to see if this specific treatment is right for their individual needs.

What this means for you:

The ponatinib and blinatumomab combination showed higher survival rates and fewer relapses in a Phase 3 trial.

Common questions

What did the study find about survival rates?

The trial found that 86% of patients receiving ponatinib and blinatumomab achieved 24-month event-free survival. In comparison, 67% of patients receiving imatinib and chemotherapy reached that same milestone. The study also showed a 90% overall survival rate for the ponatinib and blinatumomab group compared to 85% for the control group.

How did the two treatments compare regarding relapse?

The study showed a lower rate of relapse for patients receiving the combination of ponatinib and blinatumomab. Only 5% of patients in that group relapsed, while 13% of patients in the group receiving imatinib and chemotherapy experienced a relapse.

What other benefits were seen in the study?

The study showed that the ponatinib and blinatumomab group had higher rates of complete hematologic response at the end of induction (94% vs 79%) and better molecular response after consolidation (71% vs 49%). More patients in the new group also had survival with no measurable residual disease (68% vs 42%).

Study Details

Study typeRct

Sample sizen = 236

EvidenceLevel 2

Follow-up660.0 mo

PublishedOct 2026

PMID42874102

TrialNCT04722848

View Original Abstract ↓

BACKGROUND: The outcome of Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL) has greatly improved with the use of tyrosine kinase inhibitors and immunotherapy. METHODS: In this trial, we randomly assigned adult patients with Ph-positive ALL in a 2:1 ratio to receive ponatinib plus blinatumomab (intervention group) or imatinib plus chemotherapy (control group) as frontline treatment. A crossover to the intervention group was allowed for patients with persistence or reappearance of measurable residual disease in the control group. The primary end point was event-free survival. RESULTS: A total of 236 patients underwent randomization: 158 to the intervention group and 78 to the control group. The median age of the patients was 55 years (range, 24 to 82). At a median follow-up of 23.7 months, the estimated 24-month event-free survival was 86% in the intervention group and 67% in the control group (P<0.001). Survival with no measurable residual disease was 68% and 42%, respectively. At the end of induction, a complete hematologic response was observed in 94% of the patients in the intervention group and in 79% of those in the control group. After blinatumomab consolidation, a molecular response was observed in 71% and 49% of the patients, respectively. After crossover to the intervention group, 20 of 31 patients (64%) had a molecular response. Overall survival was 90% in the intervention group and 85% in the control group. The cumulative incidence of relapse was 5% and 13%, respectively. As of this report, only 19% of the patients in the intervention group had undergone hematopoietic stem-cell transplantation after having had a first complete hematologic response. CONCLUSIONS: In this phase 3 trial, a frontline chemotherapy-free targeted and immunotherapeutic approach was superior to the use of imatinib and chemotherapy. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA ALL2820 ClinicalTrials.gov number, NCT04722848.).

Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALLTrial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALLTrial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL

How this fits prior evidence

Common questions

More on Acute Lymphoblastic Leukemia

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties